Excellence Recognised: ADROSONIC Shines at Industry Awards
The awards evening brought together leaders who are shaping the future of the London Market. ADROSONIC is honoured to stand alongside Tom Downs, COO at Aventum, on his well-earned win, Elliot Arazi, Business Innovation Architect at Inigo, for his impactful nomination and Paul Richmond, Head of Customer Success at Novidea, on his richly deserved recognition.
ADROSONIC extends its sincere thanks to Roger Oldham, Founder & CEO of LMF, for creating a platform that continues to champion collaboration, leadership and meaningful progress across the market.
Adding to this moment of pride, ADROSONIC's Founder, MD & CEO, Mayank, has been honoured with the Times Leadership Award 2025 under the 'Visionary Entrepreneur' category by the Times of India Group. This award reflects his strategic foresight and the company's dedication to delivering measurable value to its clients.
Mayank commented, 'This one is for our visionary initiative on industry-academia collaboration and for setting up an innovation lab which is unique. The other factor mentioned is to recognise our organic growth without any funding and debt.'
Further strengthening ADROSONIC's commitment to excellence, Sonal, Co-Founder, COO, ADROSONIC has been honoured with the Pratishtha Award 2025, recognising her outstanding contributions and leadership in driving innovation and impact.
These recognitions are more than accolades — they affirm ADROSONIC's mission to empower stakeholders and customers alike, drive innovation and build enduring partnerships. With every milestone, ADROSONIC strengthens its resolve to deliver transformative outcomes for its customers.
Visit www.adrosonic.com for more information.
About ADROSONIC: ADROSONIC is a global IT consulting firm providing professional services to power digital transformation. ADROSONIC has offices across the globe, including India, UK, USA, Brazil and Chile. ADROSONIC has completed over 400 projects and has earned 100% client retention for over a decade.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
NEW YORK--(BUSINESS WIRE)--Third paragraph, second sentence of release should read: These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. The updated release reads: SAIF PARTNERS: NOW IS YOUR LAST CHANCE TO VOTE FOR BOARD CHANGE AT SINOVAC Sinovac's Special Meeting of Shareholders is Just Days Away; Your Vote Matters No Matter How Many Shares You Own SAIF Partners Urges Shareholders to Vote the GOLD Proxy Card ' FOR ' its Director Candidates to End Years of Chaos, Restore Credibility and Unlock Long-Term Value for All Sinovac Shareholders SAIF Partners IV L.P., ('SAIF Partners', 'we' or 'us'), the largest single investor in Sinovac Biotech Ltd. ('Sinovac' or the 'Company') which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote ' FOR ' the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the 'Board') using the GOLD proxy card. Sinovac's Special Meeting of Shareholders (the 'Special Meeting') – scheduled for Tuesday, July 8 at 8:00 p.m. Atlantic Standard Time (Wednesday, July 9 at 8:00 a.m. China Standard Time) – is just days away, and time is running out to cast your vote for change. SAIF Partners firmly believes that Sinovac's current Board – the majority of whose members were not duly elected by shareholders or sanctioned by the Privy Council – does not act in the interests of all shareholders, and in fact only began to do so when it was publicly pressured. Further, we believe the current Board lacks integrity, industry experience, management expertise, and respect for the law necessary to fulfill its lofty promises to shareholders. As such, we do not believe the current Board has the capability to resolve the Company's most pressing issues, including concluding its numerous lawsuits and ending the six-year suspension of the trading of Sinovac's common shares in the public markets. Most importantly, however, we are highly skeptical of the current Board's ability to follow through on its plan to issue significant dividends to shareholders for several concerning reasons. These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. These issues, among others, lead us to believe that the current Board has put forth its massive dividend distribution plan simply to win shareholders' support and retain their positions, even though it lacks the capabilities to follow through on its stated promise. Ultimately, we believe that meaningful change is urgently needed on Sinovac's Board to restore the Company's credibility with investors and regulators and unlock the tremendous long-term value embedded within Sinovac for all shareholders. If elected, our nominees will work closely with management to deliver shareholders the long-overdue dividends they deserve and establish a long-term business strategy that will maximize the value of the Company for all shareholders. Now is Your Chance to Elect a Board that Will Act in the Best Interest of ALL Sinovac Shareholders Vote the GOLD Proxy Card Today 'FOR' Proposal 1 and Proposal 2 to Remove Sinovac's Current Board and Elect SAIF Partners' Highly Qualified Director Candidates VISIT TO CAST YOUR VOTE USING YOUR UNIQUE CONTROL NUMBER LOCATED ON YOUR GOLD PROXY CARD. IF YOU RECEIVED A GOLD PROXY CARD BY EMAIL, CLICK THE LINK IN YOUR EMAIL TO CAST YOUR VOTE IF YOU DID NOT RECEIVE A GOLD PROXY CARD OR IF YOU HAVE LOST YOUR GOLD PROXY CARD, CHECK YOUR SPAM FOLDER OR CONTACT YOUR BROKER TO ASK FOR YOUR CONTROL NUMBER. IF YOU HAVE ALREADY VOTED USING THE COMPANY'S WHITE PROXY CARD, YOU CAN STILL CHANGE YOUR VOTE BY USING YOUR GOLD PROXY CARD. About SAIF Partners SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. Additional Information and Where to Find It This communication may be deemed to be solicitation material in respect of SAIF Partners' nomination of ten director nominees to Sinovac's Board. In connection with such solicitation, SAIF Partners mailed the definitive proxy statement and proxy card to shareholders of Sinovac with respect to the Special Meeting to be held in connection with the election of directors to Sinovac's Board. The definitive proxy statement mailed by SAIF Partners is also filed as Exhibit 1 to its Schedule 13D/A filed on or about June 16, 2025. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH SINOVAC'S SPECIAL MEETING, INCLUDING ANY DOCUMENT INCORPORATED BY REFERENCE THEREIN, CAREFULLY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE DIRECTOR NOMINEES AND THE SPECIAL MEETING AND RELATED MATTERS. Sinovac's shareholders may obtain, free of charge, the definitive version of the proxy statement, any amendments or supplements thereto, and any other relevant documents mailed by SAIF Partners in connection with the Special Meeting at
Business Wire
27 minutes ago
- Business Wire
Graco Inc. Announces Second Quarter 2025 Earnings Conference Call
MINNEAPOLIS--(BUSINESS WIRE)--Graco Inc. (NYSE: GGG) announced today that it will release its Second Quarter 2025 earnings after the New York Stock Exchange closes on Wednesday, July 23, 2025. A full-text copy of the earnings announcement will be available on the company's website at Graco management will hold a conference call, including slides via webcast, with analysts and institutional investors to discuss the results at 11 a.m. EDT / 10 a.m. CDT on Thursday, July 24, 2025. A real-time listen-only webcast of the conference call will be broadcast on the company's website and by going here: Listeners should register on the website at least 15 minutes prior to the live conference call. For those unable to listen to the live event, a replay of the webcast will be available on the company's website at ABOUT GRACO Graco Inc. supplies technology and expertise for the management of fluids in both industrial and commercial applications. It designs, manufactures and markets systems and equipment to move, measure, control, dispense and spray fluid and powder materials. A recognized leader in its specialties, Minneapolis-based Graco serves customers around the world in the manufacturing, processing, construction and maintenance industries. For additional information about Graco Inc., please visit us at
Associated Press
34 minutes ago
- Associated Press
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
HYOGO, Japan--(BUSINESS WIRE)--Jul 2, 2025-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141 (INN: pabinafusp alfa), which is in development for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome). The Phase III clinical trial is ongoing in the United States, Latin America, and Europe. ( JR-141-GS31 ) JR-141 is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in people with Hunter syndrome. JR-141 was developed using J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, which is designed to deliver biotherapeutics across the BBB into the central nervous system (CNS) to address the neurological symptoms of Hunter syndrome. 'This achievement is a milestone in the JR-141 clinical development program, as the Hunter syndrome community needs a therapy that treats the cognitive symptoms of this devastating and life-threatening disease for which there are inadequate treatment options available,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are making good progress in this global Phase III clinical trial, and we look forward to sharing the clinical data as they are available. Thank you to all the participants who are part of this clinical trial.' In March 2021, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved JR-141 (also known by the brand name IZCARGO ® ) for a lysosomal storage disorder. JR-141 is the first-ever approved ERT in the world that penetrates the BBB. About JR-141 JR-141 (INN: pabinafusp alfa) is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in subjects with Hunter syndrome. It incorporates J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, to cross the BBB through transferrin receptor-mediated transcytosis, and its uptake into cells is mediated through the mannose-6-phosphate receptor. This novel mechanism of action is expected to make JR-141 effective against the central nervous system (CNS) symptoms of Hunter syndrome. In non-clinical trials, JCR has confirmed both high-affinity binding of pabinafusp alfa to transferrin receptors and passage across the BBB into neuronal cells. In addition, JCR has confirmed enzyme uptake in various brain tissues. The company has also confirmed a reduction of substrate accumulation in the CNS and peripheral organs in an animal model of Hunter syndrome. 1,2 In several clinical trials of pabinafusp alfa, JCR obtained evidence of reducing heparan sulfate concentrations in the cerebrospinal fluid, a biomarker for assessing effectiveness against CNS symptoms; these results were consistent with those obtained in pre-clinical studies. 3 Clinical studies have also demonstrated the positive effects of pabinafusp alfa on CNS symptoms. 4,5,6 About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future. 2: Morimoto, et al. Clearance of heparin sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol. Ther. 2021; 29(5): 1853-1861. 3: Okuyama, et al. Iduronate-2-sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Mol Ther. 2020; 27(2): 456-464. 4: Okuyama, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther. 2021; 29(2): 671-679. 5: Giugliani, et al. Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: Report of a phase 2 trial in Brazil. Mol Ther. 2021; 29(7): 2378-2386. 6: Giugliani, et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II; an Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938. View source version on CONTACT: Investors & Media: JCR Pharmaceuticals Co., Ltd. Corporate Communications [email protected] KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: RESEARCH NEUROLOGY CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE SOURCE: JCR Pharmaceuticals Co., Ltd. Copyright Business Wire 2025. PUB: 07/02/2025 11:12 AM/DISC: 07/02/2025 11:12 AM
